시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 감염증 임상시험 시장 보고서(2025년)
Infectious Disease Clinical Trials Global Market Report 2025
상품코드 : 1877793
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,668,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,638,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,609,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

감염증 임상시험 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2024년의 141억 4,000만 달러로 평가되었고, 2025년에는 151억 달러, CAGR 6.7%로 성장할 것으로 예상됩니다. 지난 몇 년간의 성장은 새로운 병원체의 출현, 세계화와 여행 증가, 개발 도상 지역에서의 위생 설비에 대한 액세스 제한, 항균제 내성 증가, 정부의 백신 접종 시책 등에 의해 견인되어 왔습니다.

감염증 임상시험 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 198억 3,000만 달러에 달하고, CAGR은 7.0%를 나타낼 전망입니다. 예측 기간의 성장은 신속 진단 기술에 대한 투자 확대, 유전체 모니터링 시스템 확대, 신규 백신 플랫폼 개발 증가, 제약 회사와 생명 공학 기업 간의 협력 강화 및 감염성 질환의 현장 진단(Point of Care) 검사에 대한 수요와 관련이 있습니다. 예측기간의 주요 동향으로는 인공지능(AI)을 이용한 감염증 발생 예측, 감염증 관리에 있어서 원격의료 도입, 웨어러블 건강 모니터링 디바이스의 통합, 인간과 동물의 건강을 연결하는 원헬스 어프로치에 대한 주력, 빅데이터를 활용한 디지털 역학 확대 등을 들 수 있습니다.

헬스케어 인프라의 정비가 진행됨에 따라 향후 감염증 임상시험 시장의 성장이 지원될 것으로 예측됩니다. 의료 인프라는 의료 서비스 제공을 가능하게 하고 효과적인 질병 예방, 진단 및 치료를 지원하는 물리적 시설, 의료기기, 기술 및 교육을 받은 인력을 말합니다. 첨단 의료 서비스에 대한 수요 증가, 신흥·복잡 질환의 부담 증대, 적절한 진단·치료·예방 케어를 제공하기 위한 설비가 완비된 시설과 숙련 의료 전문가의 필요성으로부터, 헬스 케어 인프라의 개발은 확대되고 있습니다. 헬스케어 인프라는 종합적인 전염병 연구를 수행하는 데 필수적인 고급 의료시설, 전문 장비 및 연구 능력을 향상시켜 임상시험 능력을 강화합니다. 예를 들어 미국 비영리 단체인 미국 병원 협회(AHA)에 따르면 2021년 시점의 국내 병원 총수는 6,090개 시설이며, 2025년까지 6,093개 시설에 이를 것으로 예측됩니다. 이는 전국적인 의료시설의 완만한 증가를 나타내고 있으며, 이러한 의료 인프라의 확충이 감염증 임상시험 시장의 성장을 지원하고 있습니다.

감염증 임상시험 시장의 주요 기업은 항생제 후보 약물의 3상 시험을 포함한 고급 연구 프로그램 개발에 주력하고 있습니다. 이것은 희귀 부작용을 확인하고 최적의 복용량을 결정하기위한 노력입니다. 항생제 후보 약물의 3상 시험은 규제 당국의 승인 전에 약물의 안전성, 효능 및 기존 치료법과의 비교 평가를 목적으로 대규모 환자 집단을 대상으로 실시되는 후기 단계의 임상시험을 말합니다. 예를 들어, 2025년 5월에는 스위스에 본사를 둔 제약기업 로슈사가 세계적으로 심각한 원내 감염의 주요 원인인 CRAB(다중내성 세균)을 표적으로 개발한 혁신적인 테자드형 대환상 펩티드계 항생물질 'Zosurabalpin'의 3상 임상시험을 시작했습니다. Zosurabalpin은 박테리아의 외막 구축에 필요한 리포폴리사카라이드의 수송을 억제하는 독특한 작용기전을 가지고 있으며, 현재 내성의 보고는 확인되지 않았습니다. 이 국제 공동 연구는 약 400 명의 환자를 대상으로 표준 치료와 비교하여 안전성과 효능을 평가합니다. 예비 지식은 다제 내성 박테리아에 대한 강력한 활성, 높은 내약성, 양호한 약동학 특성을 확인하고, Zosurabalpin은 항생제 내성이라는 증가하는 위협에 대한 혁신적인 해결책이 될 가능성을 보여줍니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Infectious disease clinical trials refers to the structured research studies that evaluate the safety, efficacy, and optimal use of drugs, vaccines, or therapies targeting infectious diseases. These trials follow carefully designed protocols to monitor participants' responses and collect clinical data under controlled conditions. The findings contribute to advancing medical knowledge and supporting the development of effective treatments and preventive measures against infectious diseases.

The main phases of infectious disease clinical trials include phase I, phase II, phase III, and phase IV. Phase I infectious disease refers to the initial stage of clinical trials for a new drug or vaccine, rather than the infection itself. The key indications include human immunodeficiency virus, hepatitis, influenza, tuberculosis, malaria, coronavirus disease of 2019, and others. The types of studies conducted include randomized controlled trials, open label studies, double blind studies, observational studies, and cohort studies. The various drug types include antibiotics, antivirals, antifungals, vaccines, and combination therapies, which are utilized by pharmaceutical companies, biotechnology firms, contract research organizations, academic institutes, and other research entities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The infectious disease clinical trials market research report is one of a series of new reports from The Business Research Company that provides infectious disease clinical trials market statistics, including infectious disease clinical trials industry global market size, regional shares, competitors with a infectious disease clinical trials market share, detailed infectious disease clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease clinical trials industry. This infectious disease clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The infectious disease clinical trials market size has grown strongly in recent years. It will grow from $14.14 billion in 2024 to $15.1 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period is driven by the emergence of novel pathogens, globalization and increased travel, limited access to sanitation in developing regions, rising incidence of antimicrobial resistance, and government vaccination initiatives.

The infectious disease clinical trials market size is expected to see strong growth in the next few years. It will grow to $19.83 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be connected to growing investment in rapid diagnostic technologies, expansion of genomic surveillance systems, increasing development of novel vaccine platforms, rising collaborations between pharma and biotech companies, and demand for point of care infectious disease testing. Major trends in the forecast period include use of artificial intelligence in outbreak prediction, adoption of telehealth for infectious disease management, integration of wearable health monitoring devices, focus on one health approaches linking human and animal health, and expansion of digital epidemiology using big data.

The rising healthcare infrastructure is expected to support the growth of the infectious disease clinical trials market going forward. Healthcare infrastructure refers to the physical facilities, medical equipment, technologies, and trained workforce that enable the delivery of healthcare services and support effective disease prevention, diagnosis, and treatment. The development of healthcare infrastructure is increasing due to the growing demand for advanced medical services, the rising burden of emerging and complex diseases, and the need for well-equipped facilities and skilled healthcare professionals to provide timely diagnosis, treatment, and preventive care. Healthcare infrastructure strengthens clinical trial capacity by offering advanced medical facilities, specialized equipment, and improved research capabilities essential for conducting comprehensive infectious disease studies. For instance, in January 2025, according to the American Hospital Association, a United States-based nonprofit organization, the total number of hospitals in the country was 6,090 in 2021 and is projected to reach 6,093 by 2025, indicating modest growth in healthcare facilities nationwide. Therefore, the rising healthcare infrastructure is supporting the growth of the infectious disease clinical trials market.

Leading companies in the infectious disease clinical trials market are emphasizing the development of advanced research programs, such as phase 3 trials of antibiotic candidates, to identify rare side effects and determine optimal dosage levels. A phase 3 trial of antibiotic candidates represents a late-stage clinical study conducted on a large patient population to assess the drug's safety, efficacy, and comparative performance against existing treatments before regulatory approval. For example, in May 2025, Roche, a Switzerland-based pharmaceutical firm, initiated a Phase 3 clinical trial for zosurabalpin, an innovative tethered macrocyclic peptide antibiotic developed to target CRAB, a major cause of severe hospital-acquired infections globally. Zosurabalpin features a unique mechanism of action that inhibits the transport of lipopolysaccharide required for constructing the bacterial outer membrane, with no observed resistance to date. The international trial will include about 400 patients to assess its safety and efficacy relative to standard therapies. Preliminary findings have demonstrated strong activity against multidrug-resistant bacteria, high tolerability, and favorable pharmacokinetic characteristics, positioning zosurabalpin as a potentially transformative solution to the growing threat of antibiotic resistance.

In February 2025, Flourish Research LLC, a US-based multi-site clinical trial organization, acquired Diablo Clinical Research LLC for an undisclosed amount. Through this acquisition, Flourish Research LLC aims to broaden its geographic presence and diversify its therapeutic area expertise to further enhance its clinical trial capabilities. Diablo Clinical Research LLC is a US-based company that conducts infectious disease clinical trials.

Major players operating in the infectious disease clinical trials market are GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit

North America was the largest region in the infectious disease clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the infectious disease clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The infectious disease clinical trials market consists of revenues earned by entities by providing services such as patient recruitment and enrolment, data collection and management, laboratory testing and analysis, monitoring and safety oversight and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Infectious Disease Clinical Trials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on infectious disease clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for infectious disease clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The infectious disease clinical trials market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Infectious Disease Clinical Trials Market Characteristics

3. Infectious Disease Clinical Trials Market Trends And Strategies

4. Infectious Disease Clinical Trials Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Infectious Disease Clinical Trials Growth Analysis And Strategic Analysis Framework

6. Infectious Disease Clinical Trials Market Segmentation

7. Infectious Disease Clinical Trials Market Regional And Country Analysis

8. Asia-Pacific Infectious Disease Clinical Trials Market

9. China Infectious Disease Clinical Trials Market

10. India Infectious Disease Clinical Trials Market

11. Japan Infectious Disease Clinical Trials Market

12. Australia Infectious Disease Clinical Trials Market

13. Indonesia Infectious Disease Clinical Trials Market

14. South Korea Infectious Disease Clinical Trials Market

15. Western Europe Infectious Disease Clinical Trials Market

16. UK Infectious Disease Clinical Trials Market

17. Germany Infectious Disease Clinical Trials Market

18. France Infectious Disease Clinical Trials Market

19. Italy Infectious Disease Clinical Trials Market

20. Spain Infectious Disease Clinical Trials Market

21. Eastern Europe Infectious Disease Clinical Trials Market

22. Russia Infectious Disease Clinical Trials Market

23. North America Infectious Disease Clinical Trials Market

24. USA Infectious Disease Clinical Trials Market

25. Canada Infectious Disease Clinical Trials Market

26. South America Infectious Disease Clinical Trials Market

27. Brazil Infectious Disease Clinical Trials Market

28. Middle East Infectious Disease Clinical Trials Market

29. Africa Infectious Disease Clinical Trials Market

30. Infectious Disease Clinical Trials Market Competitive Landscape And Company Profiles

31. Infectious Disease Clinical Trials Market Other Major And Innovative Companies

32. Global Infectious Disease Clinical Trials Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Infectious Disease Clinical Trials Market

34. Recent Developments In The Infectious Disease Clinical Trials Market

35. Infectious Disease Clinical Trials Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기